Trial Profile

Metronomic Cyclophosphamide and Methotrexate Combined With Zoledronic Acid and Sirolimus in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma. A Phase Ib Study From the French Sarcoma Group

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Methotrexate (Primary) ; Sirolimus (Primary) ; Zoledronic acid (Primary)
Indications Advanced breast cancer; Biliary cancer; Bone metastases; Carcinoma; Osteosarcoma; Prostate cancer; Solid tumours
Focus Adverse reactions
Acronyms METZOLIMOS

22 Nov 2022 Status changed from recruiting to completed.
07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
04 May 2021 Planned End Date changed from 1 Aug 2021 to 1 Mar 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com